Antihyperglycemic Activity of Houttuynia cordata Thunb. in Streptozotocin-Induced Diabetic Rats

Table 2

Effect of HC on lipid profile of streptozotocin-induced diabetic rats on the 21st day.

Group (n=3)	Treatment (dose in mg/kg)	TC (mg/dL)	TG (mg/dL)	VLDL (mg/dL)	HDL-C (mg/dL)	LDL (mg/dL)
I	NC	89.73±3.91	82.67±4.08	16.53±0.81	38.06±1.23	35.13±2.70
II	DC	173.13±6.99^a	177.41±8.61^a	35.48±1.72^a	21.01±0.98^a	116.63±7.4^a
III	Glib (10)	96.19±4.26^b	140.13±8.08^a,b	28.02±1.61^a,b	40.96±1.31^b	27.20±3.60^b
IV	HC (100)	161.09±7.68^a,c	161.84±8.70^a	32.36±1.74^a	24.13±1.09^a,c	104.58±8.33^a,c
V	HC (200)	132.95±7.59^a,b,c,d	138.15±5.55^a,b	27.63±1.11^a,b	31.02±1.6^a,b,c,d	74.29±6.34^a,b,c,d
VI	HC (400)	116.09±6.14^b,d	106.57±4.63^b,c,d,e	21.31±0.92^b,c,d,e	35.01±1.76^b,c,d	59.76±4.51^b,c,d

Values are expressed as mean ± SEM of 6 animals in each group. One-way ANOVA showed a significant difference in drug treatment between the groups for HC for total cholesterol, triglyceride, very low density lipoprotein (VLDL), HDL-cholesterol (HDL-C), and low density lipoprotein (LDL). ^a𝑃<0.05 compared to normal control; ^b𝑃<0.05 compared to diabetic control; ^c𝑃<0.05 compared to glibenclamide; ^d𝑃<0.05 compared to HC 100; ^e𝑃<0.05 compared to HC 200 (one-way ANOVA followed by Tukey’s multiple comparison test).